Clinical Trial

MMAPPIN' Study: Multiple Myeloma Analysis For Patient-specific Insights to Dissect Disease Heterogeneity

Recruiting
View on ClinicalTrials.gov →
Summary
This is a single-center, observational study in patients with multiple myeloma, conducted both retrospectively and prospectively. The study aims to improve understanding of the biological and clinical factors that influence disease progression, relapse, and treatment resistance. The study will integrate clinical information with advanced genomic and molecular analyses, including whole genome and RNA sequencing, as well as circulating tumor markers, to identify features linked to therapy response and disease behavior. All data will be securely stored, maintaining patient confidentiality, to build a comprehensive map of multiple myeloma that may guide more personalized future treatments.
Trial Details
NCT Number NCT07582354
Lead Sponsor IRCCS Azienda Ospedaliero-Universitaria di Bologna
Conditions Myeloma Multiple
Enrollment 520 participants
Start Date 2025-10-15
Primary Completion 2026-10-15 (estimated)
Study Completion 2032-09-29 (estimated)
Updated on ClinicalTrials.gov 2026-05-12